- Home
- CEP vs MRNS Comparison
CEP vs MRNS Comparison
Compare CEP & MRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEP
- MRNS
- Stock Information
- Founded
- CEP 2020
- MRNS 2003
- Country
- CEP United States
- MRNS United States
- Employees
- CEP N/A
- MRNS N/A
- Industry
- CEP
- MRNS Biotechnology: Pharmaceutical Preparations
- Sector
- CEP
- MRNS Health Care
- Exchange
- CEP NYSE
- MRNS Nasdaq
- Market Cap
- CEP 128.4M
- MRNS 104.7M
- IPO Year
- CEP 2024
- MRNS 2014
- Fundamental
- Price
- CEP $10.05
- MRNS $1.74
- Analyst Decision
- CEP
- MRNS Buy
- Analyst Count
- CEP 0
- MRNS 9
- Target Price
- CEP N/A
- MRNS $9.75
- AVG Volume (30 Days)
- CEP 10.4K
- MRNS 751.9K
- Earning Date
- CEP 01-01-0001
- MRNS 11-05-2024
- Dividend Yield
- CEP N/A
- MRNS N/A
- EPS Growth
- CEP N/A
- MRNS N/A
- EPS
- CEP N/A
- MRNS N/A
- Revenue
- CEP N/A
- MRNS $30,263,000.00
- Revenue This Year
- CEP N/A
- MRNS $21.18
- Revenue Next Year
- CEP N/A
- MRNS $56.42
- P/E Ratio
- CEP N/A
- MRNS N/A
- Revenue Growth
- CEP N/A
- MRNS 16.56
- 52 Week Low
- CEP $9.99
- MRNS $1.05
- 52 Week High
- CEP $10.07
- MRNS $11.26
- Technical
- Relative Strength Index (RSI)
- CEP N/A
- MRNS 54.04
- Support Level
- CEP N/A
- MRNS $1.73
- Resistance Level
- CEP N/A
- MRNS $1.83
- Average True Range (ATR)
- CEP 0.00
- MRNS 0.11
- MACD
- CEP 0.00
- MRNS -0.01
- Stochastic Oscillator
- CEP 0.00
- MRNS 46.15
About CEP CANTOR EQUITY PARTNERS INC
Cantor Equity Partners Inc is a blank check company.
About MRNS Marinus Pharmaceuticals Inc.
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.